低危激素敏感乳腺癌加速部分乳腺照射的应用趋势与未充分利用:2010-2022年美国国家癌症数据库分析
本研究利用美国国家癌症数据库分析2010至2022年间符合低危标准(年龄≥50岁、激素受体阳性/HER2阴性、pT1N0、1-2级、非小叶组织学、切缘阴性)的早期乳腺癌患者接受加速部分乳腺照射(APBI)或部分乳腺照射(PBI)的趋势。2022年治疗的患者中,23.3%接受了任何形式的APBI/PBI,仅18.2%接受了30 Gy/5次外照射APBI或近距离治疗。
要点
- 低危激素敏感乳腺癌中APBI/PBI使用率从7.5%升至16.2%,但2022年仍不足1/4。
- 2022年仅18.2%患者接受30 Gy/5次外照射APBI或近距离治疗。
- 尽管证据支持,APBI/PBI在合格人群中仍显著未充分利用。
核心结论
- 低危激素受体阳性/HER2阴性乳腺癌患者中APBI/PBI使用率显著上升,但即使最近一年仍不足1/4合格患者接受APBI/PBI。
研究设计与样本
- 基于美国国家癌症数据库的回顾性队列研究,纳入2010-2022年接受切缘阴性肿块切除术和放疗的低危乳腺癌患者256,549例。
主要发现
- 256,549例患者中31,154例(12.1%)接受了APBI/PBI。
- 2022年分析的26,124例患者中,6,100例(23.3%)接受了任何形式APBI/PBI,4,778例(18.2%)接受了30 Gy/5次外照射APBI或近距离治疗。
关键数值与推荐
- 合格标准:年龄≥50岁、激素受体阳性/HER2阴性、病理T1N0、1-2级、非小叶组织学、切缘阴性。
- 2022年接受30 Gy/5次外照射APBI或近距离治疗的患者占18.2%。
临床怎么用
- 对于符合低危标准的早期乳腺癌患者,应考虑将APBI/PBI作为全乳照射的替代选项,尤其30 Gy/5次外照射APBI或近距离治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite growing evidence supporting the use of accelerated partial breast irradiation (APBI) and partial breast irradiation (PBI) for early-stage, low-risk breast cancer, utilization remains limited. This study evaluates trends and geographic variations in APBI/PBI adoption within the National Cancer Database from 2010 to 2022. METHODS AND MATERIALS: We used the National Cancer Database to identify patients who underwent margin-negative lumpectomy and radiation from 2010 to 2022 with favorable breast cancer: age ≥50 years, hormone receptor-positive/human epidermal growth factor receptor 2-negative, pathologic T1N0, grade 1-2, and nonlobular histology. Patients were stratified by the type of radiation therapy (APBI or whole breast irradiation [WBI]). The primary outcome was the annual utilization rate of accelerated partial breast irradiation (APBI/PBI) compared with WBI. RESULTS: Overall, 256,549 patients met all eligibility criteria. In this cohort, 31,154 (12.1%) received APBI/PBI. The use of APBI/PBI increased from 7.5% (2010-2017) to 16.2% (2018-2022) (P < .001). In the final year, among the 26,124 patients analyzed, 6100 (23.3%) received any form of APBI/PBI, and 4778 (18.2%) were treated with either 30 Gy/5Fx external beam APBI or brachytherapy. CONCLUSIONS: We found a significant rise in APBI/PBI use in patients with low-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Despite the increasing trend, even in the most recent year, fewer than 1 in 4 potentially eligible patients received APBI/PBI. Among patients treated in 2022, fewer than 1 in 5 patients received 30 Gy/5Fx external beam APBI or brachytherapy, the 2 forms of APBI that possess the combination of similar cancer control outcomes, greater convenience, and less toxicity compared with WBI.
引用
- Wu SP, Glaser SM, Yoon S, et al. Accelerated Partial Breast Irradiation for Low-Risk Hormone-Sensitive Breast Cancer: Trends and Underutilization in the National Cancer Database 2010-2022. Pract Radiat Oncol. 2026. PMID: 42114807. doi:10.1016/j.prro.2026.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。